For Healthcare Professionals Only
Be part of developing furmonertinib, an oral, highly brain-penetrant mutation selective EGFR inhibitor for first-line patients with non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations
A Global Phase 3 Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Mutations
ClinicalTrials.gov NCT#05607550
Furmonertinib is an investigational drug and is not approved for this indication.
a. Han, B, et al. FAVOUR: A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR Exon 20 insertions. Oral presentation at WCLC, September 2023.
Have a patient referral? Contact [email protected] or 628-277-4836
For more information about this study and where it is being conducted, please contact:
Phone Number: 628-277-4836
Email Address: [email protected]